Significant Advancements and Evolutions in Chimeric Antigen Receptor Design.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cancer immunotherapy has advanced significantly, with adoptive cell therapy (ACT) and chimeric antigen receptor (CAR) T cell therapy emerging as key strategies.
• CAR-T cells are engineered T cells that target tumor antigens, offering potential for long-term cancer remission.
• Existing CAR-T therapies face challenges like antigen escape and cytokine release syndrome, necessitating further optimization.

Purpose of the Study:

• To review challenges and innovative strategies in CAR-T cell therapy.
• To highlight advancements in CAR construct design and diverse therapeutic approaches.
• To guide researchers in the evolving field of ACT.

Main Methods:

• Systematic review of current CAR-T cell therapy literature.
• Categorization of CAR constructs based on structure and function.
• Discussion of novel CAR designs, including universal, dual, supra, enzyme-secreting, and stimulus-responsive CARs.
• Exploration of genetic engineering techniques like CRISPR/Cas9 and TALENs for CAR improvement.

Main Results:

• Significant progress in CAR-T cell therapy design and application.
• Introduction of advanced CAR types such as UNIVERSAL CARs, DUAL CARs, and SUPRA CARs.
• Development of CARs with enhanced functionalities, including enzyme secretion (catalase, heparanase) and external stimulus responsiveness (light, heat, oxygen, nanomaterials).
• Integration of genome editing technologies for improved CAR constructs.

Conclusions:

• Innovative CAR designs and therapeutic strategies are crucial for overcoming current limitations in CAR-T cell therapy.
• Advanced CAR constructs and genetic engineering hold promise for safer and more effective cancer treatments.
• Further clinical assessment of these refined approaches is essential for broader patient application.